US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% MSTR $160.01 ▲+0.00% ASML $1,867.31 ▲+0.00%
FinancialContent

Articles published by Liminatus Pharma Inc.

News headline image
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Announces Nasdaq Delisting Notification
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN
News headline image
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
From Liminatus Pharma Inc.
Via GlobeNewswire
Tickers LIMN